Fig. 6

FGF19^ΔKLB did not induce hepatic proliferation and cancer-associated signaling pathways. Four-week-old Mdr2^−/− mice were treated by daily i.p. injections of PBS, FGF19^WT or FGF19^ΔKLB (n = 5 per group) for eight weeks. (A-B) Representative images of Ki67 immunofluorescence staining (A) of livers from Mdr2-/- mice treated with PBS, FGF19^WT or FGF19 ^ΔKLB for eight weeks and its semi-quantitation. Image J was used to check for Ki67-positive hepatocytes on two to three pictures of randomly chosen regions from five different mice per group (B). (C-H) Hepatic protein expression of Ki67, PCNA, pEGFR, EGFR, pSTAT3 and STAT3 (C) as evaluated by Western blotting and its semi-quantitation (D-H) using Image J. (B, D-H) Mean ± SEM was chosen to represent the data; ***p < 0.001, ****p < 0.0001; conventional one-way ANOVA, then Tukey. The original blot image is shown in Figure S2